Emergent BioSolutions Inc

자세한 내용은 Emergent BioSolutions Inc 회사

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

회사 정보

종목 코드 EBS

회사 이름Emergent BioSolutions Inc

상장일Nov 15, 2006

CEOMr. Joseph C. (Joe) Papa

직원 수900

유형Ordinary Share

회계 연도 종료Nov 15

주소300 Professional Dr

도시GAITHERSBURG

증권 거래소NYSE Consolidated

국가United States of America

우편 번호20879

전화12406313200

웹사이트https://emergentbiosolutions.com/

종목 코드 EBS

상장일Nov 15, 2006

CEOMr. Joseph C. (Joe) Papa

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Joseph C. (Joe) Papa

President, Chief Executive Officer, Director

342.50K

+21.24%

Mr. Richard S. (Rich) Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

201.49K

-1.34%

Ms. Coleen Glessner

Executive Vice President - Quality and Ethics and Compliance

121.47K

-1.02%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

118.86K

+40.74%

Dr. Zsolt Harsanyi, Ph.D.

Independent Chairman of the Board

103.49K

+49.80%

Dr. Simon C Lowry, M.D.

Chief Medical Officer, Head of Research and Development

91.98K

+211.99%

Mr. Ronald B. Richard

Independent Director

85.27K

+67.63%

Ms. Jessica Perl

Senior Vice President, General Counsel, Corporate Secretary

68.39K

+1061.66%

Mr. Marvin L. White

Independent Director

68.25K

+101.64%

Mr. Keith A. Katkin, CPA

Independent Director

66.14K

-10.60%

이름

이름/직위

직위

주식 보유

변동

Mr. Joseph C. (Joe) Papa

President, Chief Executive Officer, Director

342.50K

+21.24%

Mr. Richard S. (Rich) Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

201.49K

-1.34%

Ms. Coleen Glessner

Executive Vice President - Quality and Ethics and Compliance

121.47K

-1.02%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

118.86K

+40.74%

Dr. Zsolt Harsanyi, Ph.D.

Independent Chairman of the Board

103.49K

+49.80%

Dr. Simon C Lowry, M.D.

Chief Medical Officer, Head of Research and Development

91.98K

+211.99%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

MCM Product sales

156.60M

70.48%

Commercial Product sales

45.30M

20.39%

Contracts and grants

20.30M

9.14%

지역별USD

이름

수익

비율

Non-U.S Government

143.40M

64.54%

U.S.Government

78.80M

35.46%

사업별

지역별

사업별USD

이름

수익

비율

MCM Product sales

156.60M

70.48%

Commercial Product sales

45.30M

20.39%

Contracts and grants

20.30M

9.14%

주식 보유 통계

마지막 업데이트: Thu, May 22

주주

주주 유형

주주

비율

The Vanguard Group, Inc.

5.92%

Millennium Management LLC

4.61%

American Century Investment Management, Inc.

4.23%

State Street Global Advisors (US)

3.15%

Dimensional Fund Advisors, L.P.

2.94%

Other

79.14%

주주

비율

The Vanguard Group, Inc.

5.92%

Millennium Management LLC

4.61%

American Century Investment Management, Inc.

4.23%

State Street Global Advisors (US)

3.15%

Dimensional Fund Advisors, L.P.

2.94%

Other

79.14%

주주 유형

주주

비율

Investment Advisor

26.89%

Investment Advisor/Hedge Fund

20.51%

Hedge Fund

14.34%

Research Firm

4.30%

Individual Investor

3.04%

Pension Fund

1.04%

Bank and Trust

0.67%

Sovereign Wealth Fund

0.17%

Venture Capital

0.16%

Other

28.88%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

443

38.62M

71.16%

-7.77M

2025Q1

472

38.22M

70.45%

-8.61M

2024Q4

475

36.31M

66.90%

-8.91M

2024Q3

485

33.46M

61.86%

-11.26M

2024Q2

503

32.16M

60.76%

-21.31M

2024Q1

512

37.52M

71.59%

-17.68M

2023Q4

531

43.49M

83.79%

-11.00M

2023Q3

581

43.88M

84.66%

-15.71M

2023Q2

596

48.59M

93.79%

-8.52M

2023Q1

682

47.08M

93.36%

-12.05M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

3.21M

5.92%

+13.30K

+0.42%

Mar 31, 2025

Millennium Management LLC

2.50M

4.61%

+1.02M

+68.87%

Mar 31, 2025

American Century Investment Management, Inc.

2.30M

4.23%

+159.91K

+7.48%

Mar 31, 2025

State Street Global Advisors (US)

1.71M

3.15%

-253.01K

-12.88%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

1.60M

2.94%

+492.58K

+44.62%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

1.58M

2.92%

-61.06K

-3.71%

Mar 31, 2025

Marshall Wace LLP

1.16M

2.13%

-170.78K

-12.85%

Mar 31, 2025

Palisade Capital Management, LLC

1.14M

2.1%

+202.86K

+21.61%

Mar 31, 2025

Oak Hill Advisors, L.P.

1.11M

2.05%

--

Mar 31, 2025

Qube Research & Technologies Ltd

1.09M

2%

+271.55K

+33.29%

Mar 31, 2025

5.840USD

Emergent BioSolutions Inc

5.840

개요

회사

금융